DaVita HealthCare Partners Inc
$ 150.90
-0.25%
24 Feb - close price
- Market Cap 10,112,916,000 USD
- Current Price $ 150.90
- High / Low $ 151.39 / 146.67
- Stock P/E 15.89
- Book Value -9.50
- EPS 9.52
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.07 %
- ROE 0.65 %
- 52 Week High 157.12
- 52 Week Low 101.00
About
DaVita Inc. provides kidney dialysis services through a network of outpatient dialysis centers in the United States.
Analyst Target Price
$151.71
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-18 | 2025-10-28 | 2025-08-05 | 2025-05-12 | 2025-02-13 | 2024-10-29 | 2024-08-06 | 2024-05-02 | 2024-02-13 | 2023-11-07 | 2023-08-03 | 2023-05-08 |
| Reported EPS | 3.4 | 2.51 | 2.95 | 2 | 2.24 | 2.59 | 2.5 | 2.26 | 1.62 | 2.62 | 1.91 | 1.25 |
| Estimated EPS | 3.1 | 3.18 | 2.75 | 2.02 | 2.13 | 2.72 | 2.54 | 1.95 | 1.59 | 2.02 | 1.69 | 1.15 |
| Surprise | 0.3 | -0.67 | 0.2 | -0.02 | 0.11 | -0.13 | -0.04 | 0.31 | 0.03 | 0.6 | 0.22 | 0.1 |
| Surprise Percentage | 9.6774% | -21.0692% | 7.2727% | -0.9901% | 5.1643% | -4.7794% | -1.5748% | 15.8974% | 1.8868% | 29.703% | 13.0178% | 8.6957% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: DVA
2026-02-24 10:50:05
This article analyzes DaVita Inc. (NYSE: DVA) after its recent earnings beat, discussing whether its strong cash flow makes it a hidden opportunity or if regulatory and GLP-1 drug risks present a value trap. It highlights the company's resilient fundamentals and capital returns, but also its sensitivity to U.S. healthcare policy and the potential long-term impact of weight-loss drugs. The article concludes that DaVita is suitable for investors who can tolerate volatility and seek differentiated healthcare exposure with a clear regulatory story.
2026-02-24 10:48:05
DaVita Inc. has once again beaten Wall Street earnings expectations and shown strong cash flow, yet its stock trades at a discount due to regulatory concerns and fears about GLP-1 weight-loss drugs. Despite these challenges, analysts are cautiously optimistic, highlighting resilient fundamentals, robust free cash flow, and potential for higher returns if regulatory fears are overblown. The article suggests that DaVita could be a valuable, albeit volatile, addition to a diversified healthcare portfolio for investors willing to accept policy-driven risks.
2026-02-24 04:51:18
DaVita Inc. has completed over $5.6 billion in share buybacks, significantly reducing its share count. This move, combined with CEO Javier Rodriguez's focus on long-term care and technology, aims to reshape the company's investment narrative. While buybacks could amplify future earnings per share, underlying operational risks and reimbursement pressures remain.
2026-02-24 03:52:24
U.S. Physical Therapy is slated to release its Q1 2026 earnings, with analysts expecting a 10.5% year-over-year revenue increase, a slowdown from the previous year's 16.6% growth. The company has a strong record of meeting revenue projections, though its stock has recently underperformed the average analyst target. The broader outpatient and specialty care sector has shown mixed results amidst economic uncertainty in 2025.
2026-02-24 03:52:24
U.S. Physical Therapy (USPH) is set to report its Q4 earnings, with analysts expecting a 10.5% year-on-year revenue growth. The company has a history of beating revenue estimates, and its stock is currently trading below the average analyst price target of $105.33. Peer companies like DaVita and Select Medical have reported mixed Q4 results, indicating a volatile environment for the outpatient & specialty care segment.
2026-02-24 03:52:17
Agilon Health (AGL) is set to report earnings this Wednesday after the bell. The company previously missed revenue and EPS estimates, and analysts expect a 3.9% year-on-year revenue decline for the upcoming quarter. Its stock has significantly underperformed peers and the broader outpatient & specialty care segment, with analysts setting a price target well above its current trading price.
